Examination of Structure-Activity Relationship of Viologen-Based Dendrimers as CXCR4 Antagonists and Gene Carriers

Autor(en): Li, Jing
Lepadatu, Ana-Maria
Zhu, Yu
Ciobanu, Marius
Wang, Yan
Asaftei, Simona C.
Oupicky, David
Stichwörter: AXIS; Biochemical Research Methods; Biochemistry & Molecular Biology; CELL LUNG-CANCER; Chemistry; Chemistry, Multidisciplinary; Chemistry, Organic; CHEMOKINE RECEPTOR CXCR4; DELIVERY; ENDOTHELIAL-CELLS; EXPRESSION; FACTOR-ALPHA; IN-VITRO; POLYMERS; TUMOR-NECROSIS-FACTOR
Erscheinungsdatum: 2014
Volumen: 25
Ausgabe: 5
Startseite: 907
Seitenende: 917
Chemokine receptors and their ligands play a central role in cancer metastasis, inflammatory disorders, and viral infections. Viologen dendrimers (VGD) emerged recently as a promising class of synthetic polycationic ligands for chemokine receptor CXCR4. The objective of this study was to evaluate the potential of VGD as novel dual-function polycations capable of simultaneous CXCR4 antagonism and gene delivery. As part of our systematic studies, we have synthesized a library of VGD with differences in molecular architecture, number of positive charges, and type of capping group. The ability of VGD to condense DNA was evaluated, and physicochemical and biological properties of the resulting polyplexes were studied. We have evaluated the effect of VGD surface charge, size, capping group, and molecular architecture on physicochemical properties of polyplexes, transfection efficiency, CXCR4 antagonism, and cytotoxicity in human epithelial osteosarcoma (U2OS) and in human liver hepatocellular carcinoma (HepG2) cells. We found that properties and behavior of the polyplexes are most dependent on the number of positive charges and molecular weight of VGD and to a lesser extent on the type of a capping group. Using TNF alpha plasmid, we have demonstrated that VGD prevents CXCR4-mediated cancer cell invasion and facilitates TNF alpha-mediated cancer cell killing. Such dual-function carriers have potential to enhance the overall therapeutic outcomes of cancer gene therapy.
ISSN: 10431802
DOI: 10.1021/bc500191q

Show full item record

Page view(s)

Last Week
Last month
checked on Mar 3, 2024

Google ScholarTM